Could an antibody finally treat long COVID?

NCT ID NCT05877508

Ongoing Disease control Sponsor: Michael Peluso, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of the monoclonal antibody AER002 can safely improve physical health in adults with Long COVID. The idea is that lingering virus or spike protein may cause ongoing symptoms, and the antibody might clear it. 36 participants will receive either AER002 or a placebo, and their physical health will be measured using a standard questionnaire at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AER002 (a monoclonal antibody)
What this could lead to: If it works, this could point toward a treatment for Long COVID by targeting lingering virus or spike protein.
What could go wrong: This is a small, early-phase trial with only 36 people, so results may not apply broadly. The antibody only works against certain virus variants, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID POST-ACUTE COVID-19 POST-ACUTE SEQUELA OF COVID-19

Contacts and locations

Locations

UCSF/Zuckerberg San Francisco General Hospital

San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.